The View on GU | with Lalani and Wallis

Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK...

Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering  immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved  counseling. The doctors finish the conversation by highl...

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial.  Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review o...

From practical risk stratification to the real-world challenges of delivering BCG, Dr. Aly-Khan Lalani and Dr. Christopher Wallis lead a conversation with Dr. Kulkarni about non-muscle invasive bladder cancer and its rapidly evolving treatment landscape.  Dr. Kulkarni is a urologic surgeon at the Princess Margaret Cancer Centre, University Health Network, and a surgeon-scientist and Assistant Prof...

In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making. The conversation also tackles the unique challenges of Upper Tract Uro...

In this episode, Dr. Aly-Khan Lalani, Dr. Christopher Wallis, and Dr. Alex Wyatt walk through the fundamentals of clinical genomics and why it matters for routine practice. They discuss which alterations matter in prostate cancer, germline vs. somatic testing, ctDNA test use cases and limits, and more. Dr. Alex Wyatt is an Associate Professor in Urologic Sciences and holds the President’s Excellen...

Dr. Aly-Khan Lalani and Dr. Christopher Wallis also discuss the RAMPART trial, LITESPARK-011, and the K-COMPASS model. This final recap episode highlights how evolving adjuvant strategies and combination sequencing are reshaping the kidney cancer landscape. Be sure to listen to Episodes 35 and 36 for the full ASCO GU recap, covering key updates in prostate and bladder cancer! The View on GU with L...

Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss practice-changing data in non-muscle invasive and muscle-invasive bladder cancer, including perioperative strategies,bladder-sparing approaches, and emerging targeted therapies. Don’t forget to watch or listen to Episode 35 and Episode 37 for updates on prostate and kidney cancer! The View on GU with Lalani & Wallis integrates key clinical...

Dr. Aly-Khan Lalani and Dr. Christopher Wallis also highlight Canadian-led innovation in the GUNS trial and early data from the PAnTHA study, and discuss how Prostate Cancer Working Group 4 may redefine trial design. Episode 35 is the first of three ASCO GU recap episodes, so don’t miss Episode 36 on bladder cancer and Episode 37 on kidney cancer! The View on GU with Lalani & Wallis integrates...

In Episode 34, Dr. Aly-Khan Lalani and Dr. Christopher Wallis sit down with Dr. Fleshner to explore how an academic surgeon transitioned from traditional clinical and research roles into medical entrepreneurship. From tackling Canada’s BCG shortage to co-founding a pharmaceutical company that sold for over a billion dollars, Dr. Fleshner walks through how he has built and scaled successful busines...

In Episode 33, Dr. Aly-Khan Lalani and Dr. Christoper Wallis sit down with Dr. Daniel Heng, Clinical Professor at the University of Calgary and Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre. Together, they explore the full landscape of mentorship and sponsorship in academic medicine, from what makes an exceptional mentee to how leaders identify and support rising ta...

Wrapping up our live ESMO 2025 coverage from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review pivotal kidney cancer data, including RAMPART’s results, emerging first-line combinations from KEYMAKER-U03 and more, offering a forward-looking view of where RCC research is heading next. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and...

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review the major ESMO 2025 prostate cancer studies, including ENZARAD, EMBARK, CAPItello-291, PSMAddition, and PR21. Together, they unpack their clinical impact and how evolving biomarkers, imaging, and treatment sequencing are redefining standards of care. The View on GU with Lalani & Wallis integrates key clinical data...

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review ESMO 2025’s bladder cancer headlines, from the evolving role of PD-1/PD-L1 inhibitors to ctDNA-guided adjuvant therapy and antibody-drug conjugates redefining metastatic management. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaning...

Ahead of ESMO 2025 in Germany, Dr. Monty Pal sits down with Dr. Aly-Khan Lalani and Dr. Chris Wallis to discuss what the oncology community can expect to see at this year’s Congress. From groundbreaking bladder cancer therapies to the newest approaches in prostate and kidney cancer, this episode explores various abstracts and presentations set to be shared in Berlin.  The View on GU with Lalani &a...

Dr. Aly-Khan Lalani and Dr. Christopher Wallis sit down with the Executive Vice-President, Evidence, Products, and Services at Canada’s Drug Agency (CDA-AMC), Sudha Kutty. In part one of this series on drug approval, they discuss health technology assessments and frameworks, how CDA-AMC balances timely access with rigorous evidence review and more. The View on GU with Lalani & Wallis integrate...

Dr. Adam Kinnaird of the University of Alberta joins Dr. Aly-Khan Lalani and Dr. Christopher Wallis to explore the evolution of prostate cancer diagnostics, from the limitations of transrectal ultrasound to the rise of MRI and micro-ultrasound. They unpack key trials, discuss real-world challenges like long MRI wait times in Canada, and examine how micro-ultrasound offers a scalable, point-of-care...

From defining what real-world evidence is to discussing its impact on cancer drug approvals, comparative effectiveness, and synthetic data, Dr. Winson Cheung shares insights with Dr. Aly-Khan Lalani and Dr. Christopher Wallis that every clinician should know. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful...

Concluding their three-episode series filmed live in Chicago, your hosts wrap up the weekend with a discussion of the key bladder cancer presentations from the 2025 ASCO Annual Meeting. They begin in the perioperative space, reviewing updated CREST data presented since AUA and revisiting the NIAGARA trial last seen at ESMO 2024, and end by covering the latest EV-302 updates in the metastatic setti...

Picking up from Episode 23, your hosts turn their focus to the highly anticipated prostate cancer presentations from the 2025 ASCO Annual Meeting in Chicago. They begin with a discussion on mCSPC, focusing on the AMPLITUDE trial, followed by results from TALAPRO-2, the ARANOTE trial, IRONMAN, and STAMPEDE. The episode wraps with key abstracts and oral presentations on mCRPC. The View on GU with La...

Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practisi...

With new bladder cancer therapies on the horizon, Dr. Lalani and Dr. Wallis review promising trial results - including EVER, CREST and the CISTO Study -presented at this year’s annual meeting. They also address key practical challenges for bladder cancer treatment, from both a medical oncologist and a urologic oncologist's perspective. The View on GU with Lalani & Wallis integrates key cli...

In this informative episode, Dr. Aly-Khan Lalani and Dr. Christopher Wallis are joined by Dr. Frédéric Pouilot, a urologist-oncologist and researcher in molecular imaging at the CHU de Québec-Université Laval Research Center. Together, they unpack the evolving role of PSMA PET in prostate cancer and how advanced imaging tools are reshaping treatment decisions. The conversation also looks ahead, to...

In this must-listen episode, your hosts are joined by Dr. Zukotynski, a Professor of Medicine and Radiology at McMaster University and staff member at Hamilton Health Sciences. With her expertise in nuclear medicine and radiology, she delves into treatment logistics, the essential role of multidisciplinary coordination, and more. The View on GU with Lalani & Wallis integrates key clinical data...

Episode 19 is the final part of a mini-series from the 2025 ASCO Genitourinary Cancers Symposium in San Francisco! After diving into prostate and bladder cancers in the first two episodes, Dr. Aly-Khan Lalani and Dr. Christopher Wallis are wrapping with an in-depth look at kidney cancer, diving into research, studies and developments shared at the symposium.  The View on GU with Lalani & Walli...